Abstracts tagged "longitudinal studies"

Abstract Number: 0343 • ACR Convergence 2021
Overview of the Childhood Systemic Lupus Erythematosus (cSLE) Cohort in the CARRA Registry
Christine Bacha¹, Anne Dennos², Andrea Knight³, Laura Schanberg⁴, Mary Beth Son⁵, Emily von Scheven⁶, Shahla Amin⁷, Charles Helmick⁸ and Aimee Hersh⁹, ¹Nationwide Children's Hospital, Grandview Heights, OH, ²Duke University, Durham, NC, ³Hospital for Sick Children, Toronto, ON, Canada, ⁴Duke University Medical Center, Durham, NC, ⁵Boston Children's Hospital, Brookline, MA, ⁶University of California San Francisco, San Francisco, CA, ⁷CARRA, Durham, NC, ⁸Centers for Disease Control and Prevention, Atlanta, GA, ⁹University of Utah, Salt Lake City, UT
Background/Purpose: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry is a multi-center, observational registry that collects demographic, clinical, and provider- and patient-reported data from…
Abstract Number: 1408 • ACR Convergence 2021
Treatment of Giant Cell Arteritis in the ARTESER Multicenter Study of 1675 Patients
Jesús T. Sánchez-Costa¹, Iñigo Hernández-Rodríguez², Elisa Fernández-Fernández³, María T. Silva-Diaz⁴, Jesús A. Valero-Jaimes⁵, Ismael González-Fernández⁶, Julio Sánchez⁷, Judit Lluch⁸, Eva Galindez-Agirregoikoa⁹, Javier Mendizábal-Mateos¹⁰, Pia M. Lois Bermejo¹¹, Javier Loricera¹², Alejandro Muñoz¹³, Cristina Valero-Martínez¹⁴, Patricia Moya¹⁵, Carmen Larena-Grijalba¹⁶, Vanessa A. Navarro-Angeles¹⁷, Joan Calvet-Fontova¹⁸, Ivette Casafont¹⁹, Francisco Ortiz-Sanjuán²⁰, Selene Labrada-Arrabal²¹, Jaime Calvo-Alén²², Carlota L. Iñiguez-Ubiaga²³, Vanesa Hernández²⁴, Cristina Campos-Fernández²⁵, María Alcalde-Villar²⁶, Antonio Juan-Mas²⁷, Eugenio De Miguel²⁸, Javier Narvaez²⁹, Miguel Ángel gonzalez-Gay³⁰, Noemí Garrido-Puñal³¹, Paula V. Estrada-Alarcon¹⁷ and Ricardo Blanco³², ¹Spanish Society of Rheumatology, Madrid, Spain, ²Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ³Rheumatology department, La Paz University Hospital, Madrid, Spain, ⁴Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, ⁵Hospital Universitario Donostia, Donostia-San Sebasti, Spain, ⁶Hospital Universitario de León, León, Spain, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, ⁹Hospital Universitario de Basurto, Bilbao, Spain, ¹⁰H. Navarra, Navarra, Spain, ¹¹Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, ¹²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹³Hospital Universitario Virgen del Rocío, Sevial, Spain, ¹⁴Hospital Universitario de La Princesa, Madrid, Spain, ¹⁵Hospital Sant Pau, Barcelona, Spain, ¹⁶Rheumatology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁷Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, ¹⁸Hospital Universitari Parc Tauli, Sabadell, Spain, ¹⁹Hospital Universitari Germans Trias i Pujol, Barcelona, Badalona, Spain, ²⁰H. La Fe, Valencia, Spain, ²¹Hospital del Mar, Barcelona, Spain, ²²Rheumatology Department, Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ²³Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁴Rheumatology Department, Hospital Universitario de Canarias, La Laguna, Spain, ²⁵Consorci Hospital General Universitari de Valencia, Valencia, Spain, ²⁶Hospital Universitario Severo Ochoa, Leganés, Spain, ²⁷Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ²⁸Hospital Universitario La Paz, Madrid, Spain, ²⁹Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³⁰Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ³¹Hospital Universitario Virgen del Rocío, Sevilla, Spain, ³²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Glucocorticoids (GC) are the mainstay therapy in Giant Cell Arteritis (GCA), initially at high doses (40-60 mg/day) followed by gradual glucocorticoid tapering. This treatment,…
Abstract Number: 0347 • ACR Convergence 2021
Longitudinal ANA Titers in SLE and ANA+ Controls
Emily Littlejohn¹, Lingxuan Kong², Kelly Speth², Lu Wang² and Emily Somers², ¹Cleveland Clinic, Cleveland, OH, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Antinuclear or anticellular antibodies (ANAs), are a hallmark of systemic lupus erythematosus (SLE). ANAs are also a marker of subclinical autoimmunity, with ~13% of…
Abstract Number: 1663 • ACR Convergence 2021
The Influence of Comorbidity on Mortality in Patients with Rheumatoid Arthritis 1980-2015: A Longitudinal Population-based Study in Western Australia
Khalid Almutairi¹, Johannes Nossent¹, David Preen¹, Helen Keen² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Australia, ²University of Western Australia, Daglish, Australia, ³University of Western Australia, Nedlands, Perth, Australia
Background/Purpose: Rheumatoid arthritis (RA) contributes to excess morbidity and mortality in RA patients compared with the general population. In Australia, there is a paucity of…
Abstract Number: 0503 • ACR Convergence 2021
18F-fluorodeoxyglucose Positron Emission Tomography as a Predictor of Angiographic Progression of Disease in Large-vessel Vasculitis
Kaitlin Quinn¹, Mark A. Ahlman², Hugh Alessi³, Ashkan Malayeri², Jamie Marko², Elaine Novakovich² and Peter Grayson⁴, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, Maryland, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: There is limited prospective data characterizing arterial lesions over time in giant cell arteritis (GCA) and Takayasu’s arteritis (TAK), the two main forms of…
Abstract Number: 1800 • ACR Convergence 2021
Altered Metabolic Profiles in the Transition from Psoriasis to Psoriatic Arthritis: A Longitudinal Analysis
Ananta Paine¹, Paul Brookes², Dongmei Li³, Somyaroop Bhattacharya⁴, Maria de la Luz Garcia-Hernandez¹ and Christopher Ritchlin¹, ¹Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ²Department of Pharmacology & Physiology, University of Rochester Medical Center, Rochester, NY, ³Department of Clinical and Translational Research, University of Rochester Medical Center, Rochester, NY, ⁴Division of Neonatology, Department of Pediatrics, University of Rochester, Rochester, NY
Background/Purpose: The transition to psoriatic arthritis (PsA) occurs in 20-30% of psoriasis (Ps) patients, but the mechanisms underlying the emergence of musculoskeletal disease are not…
Abstract Number: 0591 • ACR Convergence 2021
The Temporal Association Between Hospital Admissions, Disease-modifying Anti-rheumatic Drugs Usage and Direct Health Care Costs in Rheumatoid Arthritis Patients
Khalid Almutairi¹, Johannes Nossent¹, David Preen¹, Helen Keen² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Australia, ²University of Western Australia, Daglish, Australia, ³University of Western Australia, Nedlands, Perth, Australia
Background/Purpose: Rheumatoid arthritis (RA) carries a substantial burden for patients and society in terms of morbidity, disability, and medical expenses. The Australian Pharmaceutical Benefits Scheme…
Abstract Number: 1912 • ACR Convergence 2021
Meteorological Variables Have Different Effect on Core Measures of Disease Activity in Patients with Rheumatoid Arthritis
Peter Mandl¹, Paul Studenic², Farideh Alasti¹, Rainer Kaltenberger³, Andreas Kerschbaumer¹, Thomas Krennert³, Josef Smolen¹ and Daniel Aletaha⁴, ¹Medical University of Vienna, Vienna, Austria, ²Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, ³Central Institute for Meteorology and Geodynamics, Vienna, Austria, ⁴Medical University Vienna, Vienna, Austria
Background/Purpose: The notion that weather conditions may influence the symptoms and course of rheumatic and musculoskeletal diseases goes back to ancient times. We aimed to…
Abstract Number: 0781 • ACR Convergence 2021
Long-Term Follow-up of Juvenile Localized Scleroderma Patients Treated with Methotrexate-Based Standardized Regimens (Consensus Treatment Plans)
Suzanne Li¹, Aaron Thammavongxay², Maria Ibarra³, Kathryn Torok⁴, Polly Ferguson⁵, C Egla Rabinovich⁶, Robert Fuhlbrigge⁷, Katie Stewart⁸, Elena Pope⁹, Ronald Laxer¹⁰, Sandy Hong¹¹, Thomas Mason¹², Mara Becker¹³, Gloria Higgins¹⁴, Fatma Dedeoglu¹⁵ and for the CARRA Legacy Registry¹⁶, ¹Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, West Orange, NJ, ²Bergen Academies, Hackensack, NJ, ³Children's Mercy Hospital, Kansas City, MO, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Iowa Carver College of Medicine, Iowa City, IA, ⁶Duke Childrens Hospital & Health Center, Durham, NC, ⁷University of Colorado, Denver, CO, ⁸UT Southwestern, Dallas, TX, ⁹Hospital for Sick Kids, Toronto, ON, Canada, ¹⁰SickKids, Toronto, ON, Canada, ¹¹University of Iowa Stead Family Children's Hospital, Iowa City, IA, ¹²Mayo Clinic, Rochester, MN, ¹³Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC, ¹⁴Ohio State University, Columbus, OH, ¹⁵Boston Children's Hospital, Boston, MA, ¹⁶Childhood Arthritis and Rheumatology Research Alliance, Milwaukee, WI
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare chronic inflammatory and fibrosing disease associated with a high risk for morbidity in children. Methotrexate (MTX) has…
Abstract Number: 0810 • ACR Convergence 2021
Persistent Disease Activity Impairs Work Productivity and Non-work Activity in Recent Onset Rheumatoid Arthritis
Carol Hitchon¹, Marie-France Valois², Orit Schieir³, Susan Bartlett², Louis Bessette⁴, Gilles Boire⁵, Glen Hazlewood⁶, Edward Keystone⁷, Janet Pope⁸, Carter Thorne⁹, Diane Tin¹⁰, Vivian Bykerk¹¹ and Canadian Early Arthritis Cohort (CATCH) Investigators¹², ¹University of Manitoba, Winnipeg, MB, Canada, ²McGill University, Montréal, QC, Canada, ³Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰The Arthritis Program Research Group, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²Canadian Early Arthritis Cohort, Toronto, ON, Canada
Background/Purpose: Reduced work and activity productivity are significant contributors to the personal and societal costs associated with rheumatoid arthritis (RA). We sought to describe work…
Abstract Number: 0833 • ACR Convergence 2021
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in German Real-World Practice: Interim Results from a Post-Marketing Observational Study
Torsten Witte¹, Uta Kiltz², Florian Haas³, Elke Riechers⁴, Ulrich Prothmann⁵, Daniela Adolf⁶, Carsten Holland⁷, Rouven Hecht⁸, Alexander Rössler⁷, Kirsten Famulla⁸, Konrad Götz⁸ and Klaus Krüger⁹, ¹Hannover Medical School, Hannover, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ³Internistisch-Rheumatologische Facharztpraxis, Tübingen, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Knappschaftsklinikum Saar, Püttlingen, Germany, ⁶StatConsult GmbH, Biometry and Data Management, Magdeburg, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, ⁸AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁹Rheumatological Practice Center, Munich, Germany
Background/Purpose: Upadacitinib (UPA) is a Janus kinase inhibitor that has been shown to be effective and well tolerated in patients with rheumatoid arthritis (RA) in…
Abstract Number: 0853 • ACR Convergence 2021
A Combined Patient Registry and Biobank Laboratory Information System for Prospective Multisite Chronic Rheumatic Disease Research Using REDCap
Craig Willers¹, Tom Lynch¹, Vibhasha Chand², Mohammad Islam³, Marissa Lassere⁴, Helen Keen⁵, Tony Kenna⁶, Susan Lester⁷, Ranjeny Thomas⁸, Premarani Sinnathurai⁹, Mihir Wechalekar¹⁰, Ashley Fletcher¹¹, Daniel Lightowler¹², Sheeraz Mohd¹³, Nishta Ramnoruth¹⁴, Carlee Ruediger¹⁵, Helen Weedon¹⁶ and Lyn March¹⁷, ¹Institute of Bone and Joint Research, Kolling Institute, University of Sydney, St Leonards, Australia, ²Public Health and Preventive Medicine, Monash University, Melbourne, Australia, ³Information and Communications Technology, University of Sydney, Sydney, Australia, ⁴St George Hospital; School of Population Health, University of New South Wales, Carlton, Australia, ⁵University of Western Australia, Daglish, Australia, ⁶Queensland University of Technology, School of Biomedical Sciences, Brisbane, Australia, ⁷Rheumatology Department, The Basil Hetzel Institute, The Queen Elizabeth Hospital, Adelaide, Australia, ⁸University of Queensland, Diamantina Institute, Brisbane, Australia, ⁹Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, Sydney, Australia, ¹⁰Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, Australia, ¹¹Cabrini Health, Malvern, Australia, ¹²Medical School, University of Western Australia; Rheumatology Department, Fiona Stanley Hospital, Perth, Australia, ¹³Fiona Stanley Hospital, South Metropolitan Health Services, Perth, Australia, ¹⁴Diamantina Institute, University of Queensland, Brisbane, Australia, ¹⁵University of Adelaide; The Queen Elizabeth Hospital, Adelaide, Australia, ¹⁶Flinders University, Bedford Park, Australia, ¹⁷Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Sydney, Australia
Background/Purpose: As we enter the big data revolution, comprehensive informatics solutions are essential to realising precision medicine for rheumatic and other chronic disease patients, especially…
Abstract Number: 1000 • ACR Convergence 2020
Passive Smoking Throughout the Life Course and the Risk of Incident Rheumatoid Arthritis in Adulthood Among Women
Kazuki Yoshida¹, Jiaqi Wang², Susan Malspeis³, Bing Lu⁴, Lauren C. Prisco³, Lily Martin³, Julia Ford², Karen Costenbader⁵, Elizabeth Karlson² and Jeffrey Sparks⁶, ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Personal cigarette smoking has been strongly associated with the risk for developing seropositive RA. Previous studies concerning passive smoking conflict; some suggested that childhood…
Abstract Number: 1851 • ACR Convergence 2020
Different Disease Activity Trajectories in Early Axial Spondyloarthritis Lead to Significantly Different Long-term Outcomes : A Cluster-based Analysis of the DESIR Cohort
Benattar Leslie¹, Anna Molto², Laure Gossec³ and Resche Rigon Matthieu⁴, ¹Cochin Hospital, Paris, Paris, Ile-de-France, France, ²Rheumatology Department, Cochin Hospital, APHP, Paris, France, Paris, France, ³Sorbonne University, INSERM; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ⁴INSERM (UFR 1153), Saint Louis Hospital, Paris, Paris, France
Background/Purpose: AxSpA is a heterogeneous disease, leading to different treatment and follow-up modalities depending on the presentation, along with other elements (socio-economic, gender, etc..). In a…
Abstract Number: 1094 • ACR Convergence 2020
Long Term Open Label Extension of Study of Tofacitinib in Refractory Dermatomyositis
Julie Paik¹, Jemima Albayda¹, Eleni Tiniakou¹, Grazyna Purwin¹, Andrew Koenig² and Lisa Christopher-Stine¹, ¹Johns Hopkins University, Baltimore, MD, ²Pfizer Inc, New York City, NY
Background/Purpose: Tofacitinib is a pan-JAK inhibitor that demonstrated safety and efficacy in a 12 week open label trial of 10 subjects with refractory dermatomyositis (NCT03002649).…

« Previous Page
1
…
8
9
10
11
12
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].